Viking Therapeutics Inc (VKTX)

[greens12]

Viking Therapeutics: FY'17 Q3 Quarterly Update
"Phase II study appears to have been intelligently designed with higher dosage levels, and a longer trial length increased from 3-weeks to 12-weeks, as well as some other minor modifications - it would appear to have de-risked that primary end-point."

While this does not ensure success, intuition would be that study’s data should show a strong dose-dependent relationship with statistical significance at most if not all of the dosage levels."

https://seekingalpha.com/article/4122928-viking-therapeutics-fy17-q3-quarterly-update?li_source=LI&li_medium=liftigniter-widget